Abstract
Mast cells and basophils are major effector cells in the immunoglobulin E (IgE)-dependent allergic reactions as well as in the innate immunity. They are distributed throughout the body and, upon allergen exposure, are stimulated via the high affinity IgE receptor (FcεRI) to release several pro-inflammatory mediators such as leukotrienes, immunoregulatory cytokines and histamine. FcεRI-mediated signaling is initiated by tyrosine phosphorylation of FcεRI subunits by Src family kinase Lyn, which is followed by an activation of Syk / Zap family kinase Syk. The activated kinases then in turn phosphorylate and activate other enzymes [phospholipase Cγ (PLCγ) isoforms, phosphatidylinositol-3 kinase (PI3K) isoforms, protein kinase C (PKC) isoforms, Brutons tyrosine kinase (Btk) and others], adaptors [linker for activation of T cells (LAT), Cbl, Grb2 and others] and GTP exchange factors / GTPases (Vav, Ras, Rho, and others), and subsequently induce the mobilization of stored and extracellular Ca2+. These and other biochemical events lead within seconds and minutes to the secretory response and later to the production of chemokines. This review is focused on the use of tyrosine kinase inhibitors specific for Src family kinases (PP1 / PP2, SU6656 and CT5269), Syk kinase (piceatannol, ER-27319 and BAY 61-3606) and Btk (terreic acid and LFM-A13) for a modulation of FcεRI-mediated signaling in mast cells. Potential use of the inhibitors in the treatment of inflammatory and allergy diseases as well as future directions in the development of highly specific tyrosine kinases inhibitors of new generations and their use in an intended modulation of mast cell signaling are discussed.
Keywords: mast cell, ige receptor, signal transduction, iyn, fyn, syk, btk, kinase inhibitors
Current Pharmaceutical Design
Title: Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases
Volume: 10 Issue: 15
Author(s): Petra Luskova and Petr Draber
Affiliation:
Keywords: mast cell, ige receptor, signal transduction, iyn, fyn, syk, btk, kinase inhibitors
Abstract: Mast cells and basophils are major effector cells in the immunoglobulin E (IgE)-dependent allergic reactions as well as in the innate immunity. They are distributed throughout the body and, upon allergen exposure, are stimulated via the high affinity IgE receptor (FcεRI) to release several pro-inflammatory mediators such as leukotrienes, immunoregulatory cytokines and histamine. FcεRI-mediated signaling is initiated by tyrosine phosphorylation of FcεRI subunits by Src family kinase Lyn, which is followed by an activation of Syk / Zap family kinase Syk. The activated kinases then in turn phosphorylate and activate other enzymes [phospholipase Cγ (PLCγ) isoforms, phosphatidylinositol-3 kinase (PI3K) isoforms, protein kinase C (PKC) isoforms, Brutons tyrosine kinase (Btk) and others], adaptors [linker for activation of T cells (LAT), Cbl, Grb2 and others] and GTP exchange factors / GTPases (Vav, Ras, Rho, and others), and subsequently induce the mobilization of stored and extracellular Ca2+. These and other biochemical events lead within seconds and minutes to the secretory response and later to the production of chemokines. This review is focused on the use of tyrosine kinase inhibitors specific for Src family kinases (PP1 / PP2, SU6656 and CT5269), Syk kinase (piceatannol, ER-27319 and BAY 61-3606) and Btk (terreic acid and LFM-A13) for a modulation of FcεRI-mediated signaling in mast cells. Potential use of the inhibitors in the treatment of inflammatory and allergy diseases as well as future directions in the development of highly specific tyrosine kinases inhibitors of new generations and their use in an intended modulation of mast cell signaling are discussed.
Export Options
About this article
Cite this article as:
Luskova Petra and Draber Petr, Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases, Current Pharmaceutical Design 2004; 10 (15) . https://dx.doi.org/10.2174/1381612043384538
DOI https://dx.doi.org/10.2174/1381612043384538 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Novel P2X7 Receptor Antagonists Potentially Effective for Treatment of Inflammatory Diseases
Recent Patents on Biomarkers In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
Combinatorial Chemistry & High Throughput Screening Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry <i>Achillea millefolium</i> E.Mey: Phytochemistry and Pharmacological Profile
Current Traditional Medicine Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews New Insights into Acute and Chronic Lung Rejection
Current Respiratory Medicine Reviews Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
Medicinal Chemistry Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease
Current Neuropharmacology Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Eicosanoids in Inflammation: Biosynthesis, Pharmacology, and Therapeutic Frontiers
Current Topics in Medicinal Chemistry New Insights into the Molecular Mechanisms of Corticosteroids Actions
Current Drug Targets Vascular Effects of Ambient Pollutant Particles and Metals
Current Vascular Pharmacology Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design